Pediatric Cancer

SH 02 - Science Highlights - Pediatric Cancer


Monday, October 22
8:30 AM - 8:50 AM
Location: Room 304

Ranjit Bindra, MD, PhD

Yale University

Yale University: Associate Professor: Employee

Cybrexa Therapeutics: Stock Options

Dr. Ranjit Bindra is a physician-scientist and biotech entrepreneur at the Yale School of Medicine. Clinically, he treats adult and pediatric primary CNS tumors. In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and it has received international attention with major clinical implications. Building on this discovery, a more recent study in his laboratory was just accepted for publication in Nature Genetics, which highlights the expanding significance of this work: specific tumor-associated mutations induce the aberrant production of citric acid cycle-related metabolites, which drives genetic instability and BRCAness. Dr. Bindra is now translating this work directly into patients, in four phase I/II clinical trials, including an innovative, biomarker-driven trial specifically targeting the Adolescent/Young Adult (AYA) cancer patient population. In addition, he is lead co-PI of a 35-site, NCI-sponsored Phase II trial testing the PARP inhibitor, olaparib, in adult IDH1/2-mutant solid tumors (NCT03212274).

Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center in 2012.


Send Email for Ranjit Bindra



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Discussant